📣 VC round data is live. Check it out!

Axogen Valuation Multiples

Discover revenue and EBITDA valuation multiples for Axogen and similar public comparables like LeMaitre Vascular, Mehow Innovative, Establishment Labs, Jafron Biomedical and more.

Axogen Overview

About Axogen

Axogen Inc is engaged in the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. The company provides clinically and economically effective repair solutions for surgeons and health care providers. Its products include Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap, and Avive Soft Tissue Membrane. It also offers an Axotouch Two-Point Discriminator used to measure the innervation density of any surface area of the skin. Its products are available in the United States, Canada, Germany, the United Kingdom, Spain, and several other countries.


Founded

1977

HQ

United States

Employees

622

Financials (LTM)

Revenue: $244M
EBITDA: $29M

EV

$2B

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Axogen Financials

Axogen reported last 12-month revenue of $244M and EBITDA of $29M.

In the same LTM period, Axogen generated $182M in gross profit, $29M in EBITDA, and had net loss of ($18M).

Revenue (LTM)


Axogen P&L

In the most recent fiscal year, Axogen reported revenue of $225M and EBITDA of $26M.

Axogen is unprofitable as of last fiscal year, with gross margin of 74%, EBITDA margin of 12%, and net margin of (7%).

See analyst estimates for Axogen
LTMLast FY202320242025202620272028
Revenue$244M$225M$159M$187M$225M
Gross Profit$182M$167M$128M$142M$167M
Gross Margin75%74%80%76%74%
EBITDA$29M$26M($13M)$6M$507K
EBITDA Margin12%12%(8%)3%0%
EBIT Margin(2%)(3%)(13%)(2%)(3%)
Net Profit($18M)($16M)($22M)($10M)($16M)
Net Margin(7%)(7%)(14%)(5%)(7%)
Net Debt-$13M---

Financial data powered by Morningstar, Inc.

Axogen Stock Performance

Axogen has current market cap of $2B, and enterprise value of $2B.

Market Cap Evolution


Axogen's stock price is $39.46.

Axogen share price decreased by 0.1% in the last 30 days, and increased by 263.7% in the last year.

Axogen has an EPS (earnings per share) of $-0.30.

See more trading valuation data for Axogen
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$2B$2B1.9%-0.1%19.1%263.7%$-0.30

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Axogen Valuation Multiples

Axogen trades at 8.3x EV/Revenue multiple, and 70.1x EV/EBITDA.

See NTM and 2027E valuation multiples for Axogen

EV / Revenue (LTM)


Axogen Financial Valuation Multiples

As of June 4, 2026, Axogen has market cap of $2B and EV of $2B.

Axogen has a P/E ratio of (116.5x).

LTMLast FY202320242025202620272028
EV/Revenue8.3x9.0x12.7x10.8x9.0x
EV/EBITDA70.1x77.9x(151.4x)n/mn/m
EV/EBITn/mn/m(94.0x)n/mn/m
EV/Gross Profit11.1x12.1x15.8x14.2x12.1x
P/E(116.5x)(133.6x)(96.6x)(210.6x)(133.6x)
EV/FCFn/mn/m(97.8x)n/mn/m

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Axogen Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Axogen Margins & Growth Rates

Axogen grew revenue by 20% and EBITDA by 26% in the last fiscal year.

In the most recent fiscal year, Axogen reported gross margin of 74%, EBITDA margin of 12%, and net margin of (7%).

See estimated margins and future growth rates for Axogen

Axogen Margins

Last FY202420252026202720282029
Gross Margin74%76%74%75%
EBITDA Margin12%3%0%12%
EBIT Margin(3%)(2%)(3%)(1%)
Net Margin(7%)(5%)(7%)(8%)
FCF Margin(2%)0%(2%)4%

Axogen Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth20%18%20%20%
Gross Profit Growth21%11%18%21%
EBITDA Growth26%(146%)(92%)6347%
EBIT Growth(60%)(85%)139%(60%)
Net Profit Growth35%(54%)58%35%
FCF Growth(328%)(100%)(43573%)(328%)

Data powered by FactSet, Inc. and Morningstar, Inc.

Axogen Operational KPIs

Axogen's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.3M for the same period.

Axogen's Rule of 40 is 32% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Axogen's Rule of X is 63% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Axogen
LTMLast FY202320242025202620272028
Rule of 4031%32%---
Bessemer Rule of X59%63%---
Revenue per Employee-$0.4M---
Opex per Employee-$0.3M---
S&M Expenses to Revenue44%43%54%42%43%
G&A Expenses to Revenue19%20%22%21%20%
R&D Expenses to Revenue13%15%18%15%15%
Opex to Revenue-78%94%78%78%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Axogen Competitors

Axogen competitors include LeMaitre Vascular, Mehow Innovative, Establishment Labs, Jafron Biomedical, Jeol, GN Store Nord, Elekta, Fukuda Denshi, MicroPort and Bausch Health.

Most Axogen public comparables operate across Medical Devices, DeepTech, HealthTech and BioTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
LeMaitre Vascular7.7x7.3x21.1x23.5x
Mehow Innovative7.7x7.0x29.1x26.4x
Establishment Labs10.7x9.7x(159.9x)(2593.1x)
Jafron Biomedical6.5x6.3x13.3x13.2x
Jeol1.7x1.9x11.2x10.5x
GN Store Nord1.4x1.6x8.8x9.5x
Elekta1.5x1.5x11.4x10.8x
Fukuda Denshi1.8x1.8x6.6x-

This data is available for Pro users. Sign up to see all Axogen competitors and their valuation data.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Axogen

When was Axogen founded?Axogen was founded in 1977.
Where is Axogen headquartered?Axogen is headquartered in United States.
How many employees does Axogen have?As of today, Axogen has over 622 employees.
Who is the CEO of Axogen?Axogen's CEO is Michael J. Dale.
Is Axogen publicly listed?Yes, Axogen is a public company listed on Nasdaq.
What is the stock symbol of Axogen?Axogen trades under AXGN ticker.
When did Axogen go public?Axogen went public in 1986.
Who are competitors of Axogen?Axogen main competitors include LeMaitre Vascular, Mehow Innovative, Establishment Labs, Jafron Biomedical, Jeol, GN Store Nord, Elekta, Fukuda Denshi, MicroPort, Bausch Health.
What is the current market cap of Axogen?Axogen's current market cap is $2B.
What is the current revenue of Axogen?Axogen's last 12 months revenue is $244M.
What is the current revenue growth of Axogen?Axogen revenue growth (NTM/LTM) is 19%.
What is the current EV/Revenue multiple of Axogen?Current revenue multiple of Axogen is 8.3x.
What is the current EBITDA of Axogen?Axogen's last 12 months EBITDA is $29M.
What is Axogen's EBITDA margin?Axogen's last 12 months EBITDA margin is 12%.
What is the current EV/EBITDA multiple of Axogen?Current EBITDA multiple of Axogen is 70.1x.
What is the current FCF of Axogen?Axogen's last 12 months FCF is $379K.
What is Axogen's FCF margin?Axogen's last 12 months FCF margin is 0%.
What is the current EV/FCF multiple of Axogen?Current FCF multiple of Axogen is 5324.4x.
How many companies Axogen has acquired to date?Axogen hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Axogen has invested to date?Axogen hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Axogen

Lists including Axogen

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial